智通财经APP讯，浩森金融科技(03848)发布公告，于2025年12月17日，公司间接全资附属公司浩森小额 贷款与借款人邓建华订立贷款融资协议，据此，贷款人同意向借款人授出贷款融资，金额为人民币3330 万元，年利率为9%，由贷款融资协议日期起，为期15个月。 ...

格隆汇12月17日丨绿茶集团(06831.HK)公告，12月17日耗资62.6万港元回购10万股。 ...

格隆汇12月17日丨赤子城科技(09911.HK)公告，于2023年4月28日至2025年12月10日期间，Three D Partners Limited从市场购买合共114,082,000股股份。此后，于2025年12月11日至12月17日，Three D Partners Limited根据股份购买进一步从市场购买合共532,000股股份。Three D Partners Limited将持有根 据股份购买所购买的股票，直到其按照受限制股份单位奖励计划归属。 ...

中国诚通发展集团(00217)发布公告，于2025年12月17日，诚通融资租赁(公司间接全资附属公司)与承租 人(内蒙古华电巴音风力发电有限公司)订立售后回租协议，据此，诚通融资租赁将向承租人购买租赁资 产，并将租赁资产回租予承租人，租赁期为期2年，但可根据售后回租协议的条款及条件提早终止。租 赁资产指若干风力发电设备。 ...

Core Viewpoint - The company, Far East Pharmaceutical, has received formal approval from the U.S. FDA to initiate Phase I/II clinical trials for its self-developed global innovative FAP-targeted radiopharmaceutical conjugate (RDC) GPN01530 for the diagnosis of solid tumors, marking its first FDA-approved self-researched RDC product [1] Group 1 - The FDA approval is a significant milestone for the company, indicating progress in its research and development efforts [1] - GPN01530 is specifically designed for the diagnosis of solid tumors, highlighting the company's focus on oncology [1] - This approval may enhance the company's position in the competitive pharmaceutical market, particularly in the field of radiopharmaceuticals [1]

浩森金融科技(03848)发布公告，于2025年12月17日，公司间接全资附属公司浩森小额贷款与借款人邓 建华订立贷款融资协议，据此，贷款人同意向借款人授出贷款融资，金额为人民币3330万元，年利率为 9%，由贷款融资协议日期起，为期15个月。 ...

冠军科技集团(00092)发布公告，于2025年12月17日，除过往出售事项外，公司在市场上出售合共172万 股中国星股份，平均价格为每股中国星股份2.49港元，总代价约为428.5万港元(不包括交易成本)。 ...

绿茶集团(06831)发布公告，于2025年12月17日斥资62.59万港元回购10.04万股。 ...

智通财经APP讯，绿茶集团(06831)发布公告，于2025年12月17日斥资62.59万港元回购10.04万股。 ...

Core Viewpoint - The approval of GPN01530 by the FDA marks a significant milestone for the company, showcasing its capabilities in nuclear medicine and international clinical development [2][5] Group 1: Product Development - GPN01530 is the company's first self-developed radiopharmaceutical to receive FDA approval for clinical research, specifically for diagnosing solid tumors [2] - The drug demonstrates improved tumor targeting and pharmacokinetic properties compared to other FAP ligands, with preclinical studies indicating good safety and effective tumor uptake [3] - The product has shown superior clinical imaging contrast and accuracy in detecting positive lesions compared to 18F-FDG in early human studies [3] Group 2: Market Potential - The global cancer drug market is projected to grow from $150.3 billion in 2020 to $253.3 billion by 2024, with a compound annual growth rate (CAGR) of 13.9%, and is expected to reach $452.5 billion by 2030 [3] - The number of new cancer cases worldwide is estimated to rise from approximately 20 million in 2022 to nearly 24 million by 2030, indicating a significant market opportunity for cancer treatment drugs [3] Group 3: Industry Position - The global nuclear medicine industry is entering a period of rapid growth, driven by advancements in imaging technology and an aging population [4] - The company has established a comprehensive global nuclear medicine supply chain, including R&D, production, distribution, and sales, with bases in Boston and Chengdu [4] - GPN01530 is the first product from the Chengdu nuclear medicine base to enter FDA clinical stages, highlighting the platform's capabilities in preclinical development and international registration [5]